Pharmaceutical

2025 ASCO: Major Breakthroughs in Gastric Cancer Treatment: Latest Advances Preview ASCO Market Trend Cancer Discover the latest breakthroughs in gastric cancer treatment from the 2025 ASCO Annual Meeting, including immunotherapy, targeted therapies, and CAR-T advances improving survival and hope for patients worldwide.
ASCO 2025: Postoperative ctDNA in Pancreatic & Oral Cancer, Desmoid Tumor Therapy ASCO Market Trend Postoperative ctDNA-based MRD predicts recurrence in pancreatic and oral cancers, guiding personalized therapy. Radiotherapy plus bevacizumab shows efficacy in desmoid tumors with ATR mutation as a key predictor.
2025 ASCO: Domestic ADCs, Bispecifics, Trispecifics, Small Molecules ASCO Market Trend Explore the major highlights from ASCO 2025, featuring cutting-edge Chinese innovations in ADCs, bispecific and trispecific antibodies, and small molecule drugs with promising clinical trial results across multiple cancer types.
ASCO 2025: Latest Clinical Advances in Solid Tumor CAR-T Therapies from China and the U.S. ASCO Market Trend CAR-T Explore key updates from ASCO 2025 on solid tumor CAR-T therapies, including clinical trial data from leading Chinese firms and U.S. companies like A2 Bio, showcasing promising safety and efficacy results.
Four Biotechs Face Challenges Amid U.S. COVID-19 Vaccine Funding Cuts FDA WHO Biotech U.S. COVID-19 vaccine biotechs face funding cuts, regulatory changes, and operational challenges. Learn how Vaxart, Novavax, GeoVax, and CastleVax navigate this uncertain landscape impacting future pandemic preparedness.
ASCO 2025: Breakthrough Cancer Trials, Innovative Therapies, and China's Rising Role ASCO Market Trend The 2025 ASCO meeting highlights breakthrough cancer trials, including advances in breast and blood cancers, innovative bispecific antibodies, radiopharmaceuticals, and China’s growing influence in oncology innovation.
TCG Labs' Juri Biosciences Secures $210M Deal for EpimAb’s Prostate Cancer Therapy EpimAb Biotherapeutics Juri Biosciences TCG Labs Soleil’s Juri Biosciences secures up to $210M licensing deal with EpimAb Biotherapeutics for a novel T-cell engager targeting metastatic prostate cancer, advancing innovative multispecific antibody therapy.
Novartis Deepens China Ties with Eye Drug Pact Novatis SPHChina Novartis has expanded its strategic collaboration with Shanghai Pharma to promote ophthalmic drugs in China, aiming to enhance market coverage and accelerate growth as it targets a top-three pharma position in the country.
Eli Lilly Acquires SiteOne in $1B Pain Drug Deal Eli Lilly SiteOne Therapeutics Eli Lilly has acquired SiteOne Therapeutics in a deal worth up to $1 billion to develop STC-004, a promising non-opioid NaV1.8 inhibitor for chronic pain, advancing next-gen, addiction-free pain therapies.
FDA Halts Rocket’s Gene Therapy Trial After Fatality FDA Rocket Biotech Rocket Pharmaceuticals faces an FDA clinical hold on its gene therapy trial for Danon disease following a patient death. The company is reassessing its approach and extending its financial runway into 2027.